In recent years, there has been a resurgence of interest in targeting the glucose‐dependent insulinotropic polypeptide receptor (GIPR), alongside the glucagon‐like peptide 1 receptor (GLP‐1R), for the treatment of metabolic disease. This evidence concerns the gene GIPR and Other metabolic disease.